Novartis's ARNI heart failure drug shines in PhIII
This article was originally published in Scrip
Executive Summary
A major Phase III trial of Novartis's first-in-class candidate for chronic heart failure, LCZ696, is to close early because the evidence of its efficacy is so clear. Shares in the Swiss firm rose by 3.17% on the news on the morning of 31 March to CHF74.75 as experts suggested that the standard of care for heart failure might be about to change.